Forfivo XL Shortage Update: What Patients Need to Know in 2026

Patients prescribed Forfivo XL (bupropion hydrochloride 450 mg extended-release) increasingly report difficulty getting their prescription filled. This guide provides the 2026 shortage update: the current status, the reasons behind access problems, and the most effective steps you can take to protect your treatment continuity.

Current Status: Is Forfivo XL in an Active Shortage?

As of 2026, Forfivo XL is NOT listed on the FDA's or ASHP's (American Society of Health-System Pharmacists) official drug shortage databases. This means there is no declared supply crisis from a manufacturing or distribution standpoint. However, patients are still experiencing access problems — and those problems are real.

The distinction matters: "no active shortage" does not mean Forfivo XL is easy to get. The access challenges are driven by commercial and structural factors that feel very much like a shortage for the patient trying to fill their prescription.

Why Patients Are Still Struggling to Fill Forfivo XL in 2026

Three main factors create Forfivo XL's access problem in 2026:

Insurance formulary exclusions. Express Scripts placed Forfivo XL on its 2025 National Preferred Formulary Exclusion List. When a large PBM excludes a drug, millions of commercially insured patients lose access unless they qualify for a medical exception. Other PBMs may have similar restrictions. Always check your specific plan's formulary.

Low routine pharmacy stocking. Because Forfivo XL's patient population is smaller (it cannot be used to initiate therapy, only as a step-up formulation), most pharmacies don't stock it on their shelves regularly. When a prescription comes in, it may take 3-5 business days for the pharmacy to receive it from their wholesaler.

High cash price. At retail prices of $395-$566 for a 30-day supply, Forfivo XL is cost-prohibitive without insurance. Even with discount coupons (GoodRx brings it to ~$132-$133), it remains far more expensive than generic bupropion alternatives.

Background: What Is Forfivo XL and Who Is It For?

Forfivo XL is manufactured by Almatica Pharma and contains bupropion hydrochloride, an aminoketone antidepressant that works by inhibiting the reuptake of norepinephrine and dopamine. It is the only commercially available single-tablet formulation at the 450 mg dose. The FDA initially approved bupropion under the Wellbutrin brand in 1985; Forfivo XL was approved as a separate product for the 450 mg strength.

Forfivo XL is intended for adults with major depressive disorder who have already been stabilized on 300 mg/day of another bupropion formulation for at least two weeks and require a higher dose. Because of this requirement, it serves a specific subset of bupropion patients.

How This Compares to a True Drug Shortage

A true drug shortage — as seen with certain ADHD medications, chemotherapy agents, or IV fluids — typically involves manufacturing failures, API (active pharmaceutical ingredient) supply chain disruptions, or DEA quota limitations. Forfivo XL's access problem is different: the drug is being manufactured and distributed, but commercial decisions by insurance companies and pharmacies are creating barriers for patients.

This means the FDA shortage database — which tracks manufacturing-level supply failures — won't reflect the access problems many Forfivo XL patients are experiencing. Checking FDA.gov and seeing no shortage listed doesn't mean your experience of not being able to get it is wrong.

What Patients Should Do Right Now

Check your insurance formulary. Log in to your insurance member portal or call member services to find out if Forfivo XL is covered under your specific plan. If it is excluded, ask about the exception process.

Ask your prescriber about a prior authorization. If your insurer excluded it but you have a clinical reason for requiring the single-tablet 450 mg formulation (e.g., pill burden, adherence issues with two tablets), your prescriber can document this and submit a PA request.

Use the manufacturer savings card. If you have commercial insurance, Almatica's copay savings program lets patients pay $28 per fill, with the card covering up to an additional $50. Call 1-866-450-3277 for processing questions.

Consider switching to generic bupropion XL. Generic bupropion XL (300 mg + 150 mg) is clinically equivalent, widely available, and costs under $20/month with coupons. This may be the most practical long-term solution.

Use medfinder to find a stocking pharmacy. If you want to stay on Forfivo XL, medfinder can identify which pharmacies near you have it in stock, without you having to make the calls yourself.

Will the Forfivo XL Situation Improve?

Because the access issues are primarily driven by insurance decisions rather than supply chain failures, improvement depends on PBM formulary decisions and manufacturer negotiations — not manufacturing capacity. While the situation could improve if Almatica negotiates better formulary placement, patients should plan for the current environment to persist in the near term.

How medfinder Helps Patients Navigate This

medfinder was built for exactly this kind of situation. When a medication isn't reliably stocked — whether due to a true shortage or commercial factors — medfinder calls pharmacies near you and tells you which ones have your prescription available. You provide your medication, dose, and ZIP code. We handle the calls and text you the results. It's that simple.

For more actionable strategies, see our guide: How to find Forfivo XL in stock near you.